Cancer tissue sample microarray expression data typically possess a common property---the number of samples is much smaller than the number of features---here those features are genes[@b1]. Informative gene selection has important implications for the improvement of cancer diagnosis, the selection of targeted therapeutics, and the identification of new drug targets[@b2][@b3]. Individual-gene-ranking methods, such as the *t* test for binary class differentiation[@b4] and the *F* test for multi-class differentiation rank genes by comparing the expression values of the same individual gene between different classes. Although these individual-gene methods may discover individual effect genes efficiently, they may have ignored interactions (*i.e*., redundancy and synergy) between genes[@b4][@b5][@b6]. The interactions between genes are critical in pathway dysregulations which trigger carcinogenesis[@b7]. [Table 1](#t1){ref-type="table"} illustrates an example case of synergy between Gene *X*~1~ and Gene *X*~2~: 1) Knowledge regarding the state of only one of these two variables leaves the state of *Y* uncertain. 2) When states of both *X*~1~ and *X*~2~ are known, then the state of *Y* becomes certain.

Pair-wise gene evaluation has been implemented in several popular algorithms, including top scoring pair (TSP)[@b8][@b9], top scoring genes (TSG)[@b2], and doublets (*sum*, *diff*, *mul* and *sign*)[@b7], which all compare expression values of the same sample between two different genes. However, these methods are incapable of discovering pair-wise interactions efficiently. For example, let *X*~1~ and *X*~2~ be two independent random variables; *Y* equals \|*X*~1~--*X*~2~\| and is binarized with a median ([Fig. 1](#f1){ref-type="fig"}). Then, the Δ-score for TSP is 0.04, the *χ*^2^-score for TSG is 0.18, and the *t*-score is 0.04, 0.18, 3.42, and 0.56 for *sum*, *diff*, *mul*, and *sign*, respectively. The synergic pairs, *X*~1~ and *X*~2~, cannot be highlighted with these low scores calculated by these methods.

Based on information theory, the measure of *I*(*X*~1~; *X*~2~; *Y*)[@b10][@b11] can be used to identify pair-wise interactions[@b12][@b13][@b14]. The interaction of a gene pair with respect to cancer is defined as

Where *I* is the symbol for mutual information (MI), *X*~1~ and *X*~2~ are random variables representing the expression levels of the two genes and *Y* is a binary random variable representing the presence or absence of cancer[@b15]. A positive value of *I*(*X*~1~; *X*~2~; *Y*) indicates synergistic interactions, while a negative value of *I*(*X*~1~; *X*~2~; *Y*) indicates redundant interactions.

Several efforts have recently been made to discover pair-wise synergy even multivariate synergy among interacting genes on experimental biological data. The Anastassiou group proposed a systems-based approach called Entropy Minimization and Boolean Parsimony (EMBP) to identify modules of genes that are jointly associated with a phenotype from gene expression data[@b15] and SNP data[@b16]. Anastassiou[@b11] emphasized the significance of multivariate analysis such as EMBP for molecular systems biology and clarified the fundamental concepts by explaining the precise physical meaning. Watkinson *et al*.[@b17] presented a novel dendrogram-based technique to identify synergies of pairwise genes. Hanczar *et al*.[@b18] devised a histogram-based method called FeatKNN to detect the joint effect *I*(*X*~1~, *X*~2~; *Y*). Park *et al*.[@b19] proposed a new approach for inferring combinatorial Boolean rules of gene sets for cancer classification by using a synergy network. Shiraishi *et al*.[@b20] presented a rank-based non-parametric statistical test for measuring synergistic combinations between two gene sets. Ignac *et al*.[@b21] used interaction distances (ID) to identify the most synergic pairs of markers such as SNPs.

Binarization of continuous expression data simplifies the estimation of MI and provides simple logical functions connecting the genes within the found modules[@b2][@b15]. However, there are multitype complicated patterns in both real-world data ([Fig. 2A,B](#f2){ref-type="fig"}) and simulation data ([Fig. 2C,D](#f2){ref-type="fig"}); binarization might lead to loss of information[@b11][@b21]. For example, the *IGLC1* gene for the prostate dataset must be trinarized, rather than binarized ([Fig. 2C](#f2){ref-type="fig"}). Several methods have been proposed for the MI estimation, such as kernel density estimation[@b22], histogram-based technique[@b23], *k*-nearest-neighbor estimator[@b24], B-spline functions[@b25], Edgeworth[@b26], adaptive partitioning[@b27][@b28] and dendrogram-based method[@b17]. Khan *et al*.[@b29] evaluated the relative performance of several MI estimation methods, and suggested that the most suitable estimation procedure would depend on known data or domain characteristics and exploratory data analysis. Recently, Reshef *et al*.[@b30] presented a novel estimator for two variables called maximal information coefficient (MIC). MIC explores various binning strategies with different numbers of bins, and can capture a wide range of associations, both functional and non-functional, regardless of linear or non-linear relationships. Due to its generality, MIC is becoming widely accepted in scientific research fields[@b31]. Therefore, there is a large demand for extending MIC from two variables to three variables, even multivariate, to capture a wide range of synergistic interactions[@b32].

In this paper, we first developed and described an algorithm to compute *MIC*(*X*~1~; *X*~2~; *Y*). We demonstrated the generality of *MIC*(*X*~1~; *X*~2~; *Y*) with simulation data. We identified the most synergic pairs of genes (not discovered by popular feature selection approaches) using *MIC*(*X*~1~; *X*~2~; *Y*) with several real-world, cancer gene expression profile datasets. Finally, we validated these synergic genes using classification performance, Gene Ontology annotation (GO), and the OUgene database[@b33].

Calculation of *MIC*(*X* ~1~; *X* ~2~; *Y*) where *Y* is a discrete variable
============================================================================

Preliminary
-----------

Given a finite set *D*~*n*\ ×\ 3~ = {(x~1~, x~2~, y)\| x~1~ ∈ *X*~1~, x~2~ ∈ *X*~2~, y ∈ *Y*}, where *n* is the sample size, *X*~1~ and *X*~2~ are two continuous independent variables, *Y* is the discrete dependent variable *Y* = {*class*~1~, *class*~2~,\..., *class*~*P*~}, and *P* is the number of classes, we can partition *X*~1~, *X*~2~, and *Y* into *x*~1~ bins, *x*~2~ bins, and *y* bins, respectively. Here, *y* is fixed as *P*, because *Y* is a discrete variable. We denote such a partition *x*~1~-by-*x*~2~-by-*y* as grid *G*, and the distribution of the data points in *D* on the cells of *G* as *D*^\|^~*G*~.

***Definition 1*** For a finite set and positive integers *x*~1~, *x*~2~, *y*, define

where the maximum is over all grids *G* with *x*~1~-by-*x*~2~-by-*y*, and *I*(*D*\|~*G*~) is the *interaction* defined in formula (1).

***Definition 2*** The *characteristic matrix M*(*D*) of a set *D* of three-variable data is an infinite matrix with entries

***Definitions 3*** The *maximal interaction coefficient MIC*(*X*~1~; *X*~2~; *Y*) of a set *D* of three-variable data with sample size *n* and grid size less than *B*(*n*) is defined as

In this paper *a* equals 0.6, the default setting suggested by Reshef *et al*.[@b30].

The maximal grid size *B*(*n*) and normalization of *MIC*(*X* ~1~; *X* ~2~; *Y*)
--------------------------------------------------------------------------------

Formula (1) can be rewritten as

Here *I*(*X*~2~, *Y*\|*X*~1~) and *I*(*X*~1~, *Y*\|*X*~2~)are conditional mutual information.

According to formula (5) and knowing that the *X*~1~, x~1~-axis partition is fixed, *i.e.* that *X*~1~ is equipartitioned with *x*~1~ bins, the set *D* of three-variable data with sample size *n* can be subdivided into *x*~1~ subsets, and each subset has only two-variable (*X*~2~ and *Y*) and *n*/*x*~1~ samples. The mutual information for each subset can be normalized with log(min{*x*~2~, *y*}) and the maximal grid size *B*(*n*) for each subset should be (*n*/*x*~1~)^*a*^. Therefore, for set *D*, while the x~1~-axis partition is fixed, the normalization benchmark and *B*(*n*) are log (min{*x*~2~, *y*}) and (*n*/*x*~1~)^*a*^, respectively.

Similarly, for set *D* where the x~2~-axis partition is fixed, the normalization benchmark and *B*(*n*) are log (min{*x*~1~, *y*}) and (*n*/*x*~2~)^*a*^, respectively.

Approximation algorithm for *MIC*(*X* ~1~; *X* ~2~; *Y*)
--------------------------------------------------------

Here, we describe the heuristic algorithm, ApproxCharateristicMatrix_3D, for approximating the optimal *MIC*(*X*~1~; *X*~2~; *Y*). It includes four sub-algorithms: EquipartitionX1Axis, SortInIncreasingOrderByX2Value, GetSuperclumpsPartition_3D, and ApproxOptimizeX2Axis. In the dataset *D*, the first and second columns represent *X*~*1*~ and *X*~2~ respectively; the last column represents *Y*. *n* is the sample size. *B* defines the maximal grid size. The symbol "⊥" represents the dataset which is changed from (*a*~1~, *b*~1~, *z*~1~) to (*b*~1~, *a*~1~, *z*~1~). *c* represents the candidate partition point for x-axis. "log" is base-2 logarithm. x~fix~, representing the corresponding x-axis partition, is fixed (x~fix~ ∈ {x~1~, x~2~}). The symbol " ← " is an assignment operator.

EquipartitionX1Axis, SortInIncreasingOrderByX2Value and ApproxOptimizeX2Axis are nearly the same as EquipartitionYAxis, SortInIncreasingOrderByXValue, and ApproxOptimizeXAxis in Reshef *et al*.[@b30], respectively, except that ApproxOptimizeX2Axis uses *I*(*X*~1~; *X*~2~; *Y*) in place of *I*(*X*; *Y*). Here we demonstrate an example of a superclumps partition (see [Fig. 3](#f3){ref-type="fig"}) and list only the pseudo-code of GetSuperclumpsPartition_3D, which is our core algorithm for calculating interactions. The algorithm includes three steps: 1) divide the data into *P* parts according to *Y*; 2) fix an equipartition of size *x*~1~ on x~1~-axis; and 3) ensure points in the same superclump to be a unit in the same *class*, with the rank of x~2~-axis.

Results
=======

Generality of *MIC*(*X* ~1~; *X* ~2~; *Y*) according to simulation analysis
---------------------------------------------------------------------------

If *X*~1~ and *X*~2~ are statistically independent of *Y*, *MIC*(*X*~1~; *X*~2~; *Y*) should be close to 0. For example, let *X* and *Y* be two independent, random variables and *Y* is binarized with a median (sample size *n* = 200 and 500 replicates), then *MIC*(*X*; *Y*) = 0.1702 ± 0.0292. Similarly, let *X*~1~, *X*~2~ and *Y* be three independent, random variables, then *MIC*(*X*~1~; *X*~2~; *Y*) = 0.1562 ± 0.0230. *MIC*(*X*~1~; *X*~2~; *Y*) is reasonable in scope compared with *MIC*(*X*; *Y*), and decreases as the sample size grows (0.0596 ± 0.0012, *n* = 20000) and finally converges to 0.

If the state of *Y* is completely determined by the *synergy* between *X*~1~ and *X*~2~, then *MIC*(*X*~1~; *X*~2~; *Y*) should be 1, and *MIC*(*X*; *Y*) should be close to 0. As shown in [Fig. 4](#f4){ref-type="fig"}, *MIC*(*X*~1~; *X*~2~; *Y*) = 1, *MIC*(*X*~1~;*Y*)  = 0.0379 and *MIC*(*X*~2~; *Y*) = 0.0533. If *Y* is a noiseless function of *X*~1~ and *X*~2~, and *X*~1~ is fully redundant of *X*~2~, then *MIC*(*X*~1~; *X*~2~; *Y*) should be −1. For example, and *X*~1~ = *X*~2~, *MIC*(*X*~1~; *X*~2~; *Y*) = −1, *MIC*(*X*~1~;*Y*) = 1 and *MIC*(*X*~2~;*Y*) = 1.

If *Y* is a noiseless function of *X*~1~ and X~2~, then the joint effect, *i.e.*, the sum of *MIC*(*X*~1~; *X*~2~; *Y*), *MIC*(*X*~1~; *Y*) and *MIC*(*X*~2~; *Y*), should be 1. Scores of the three components and the joint effect for 10 noiseless functions ([Fig. 5](#f5){ref-type="fig"}) are listed in [Table 2](#t2){ref-type="table"}. All of the joint effects are close to 1 (0.9672\~1.1675). This indicates that the value of *MIC*(*X*~1~; *X*~2~; *Y*) calculated with ApproxCharateristicMatrix_3D is credible, while the value of *MIC*(*X*; *Y*) calculated with ApproxMaxMI[@b30] has been widely accepted. From all of the above, we deduce that *MIC*(*X*~1~; *X*~2~; *Y*) can capture a wide range of *interactions*, not limited to specific function types. That is, *MIC*(*X*~1~; *X*~2~; *Y*) has the property of generality.

Informative genes of synergy pairs discovered by *MIC*(*X* ~1~; *X* ~2~; *Y*)
-----------------------------------------------------------------------------

We employ *MIC*(*X*~1~; *X*~2~; *Y*) to detect pair-wise synergic genes in three real-world datasets. The literature resources, sample size, number of genes, and the number samples of each class in each dataset are summarized in [Table 3](#t3){ref-type="table"}.

Four popular gene selection methods, including *MIC*(*X*; *Y*), minimum-redundancy maximum-relevancy (mRMR)[@b34], support vector machine recursive feature elimination (SVM-RFE)[@b35][@b36] and TSG^2^, are chosen to compare with *MIC*(*X*~1~; *X*~2~; *Y*). The *MIC*(*X*; *Y*) estimator (setting *a* = 0.6 and *c* = 5) of Reshef *et al*.[@b30] is available at <http://www.exploredata.net/>, MIQ-MRMR is available at <http://home.penglab.com/>, and an *R* Package implementation of SVM-RFE is available at <http://www.uccor.edu.ar/paginas/seminarios/software/SVM-RFE.zip>. The TSG algorithm from our previous report[@b2] is available upon request.

Each reference method ranks the top 200 genes (Top200s) for each dataset (Top200s are shown in the [Supplementary Material Table S1-S3](#S1){ref-type="supplementary-material"}). The Top200s identified by different reference methods are compared with each other. We can observe significant overlaps between the Top 200s selected by the four reference methods, as shown in [Figs 6](#f6){ref-type="fig"}, [7](#f7){ref-type="fig"} and [8](#f8){ref-type="fig"}. This indicates that a considerable number of similar informative genes can be detected by these reference methods. *MIC*(*X*; *Y*) is an individual-gene-filter method and can only highlight genes that are individually discriminant. Although mRMR, SVM-RFE and TSG are not individual-gene-filter methods; the Top200s selected by them have considerable similarities to the Top200s selected by *MIC*(*X*; *Y*). This indicates that these methods can efficiently discover genes that are individually discriminant, but not specific to the genes have pair-wise synergy effects.

Now, we employ *MIC*(*X*~1~; *X*~2~; *Y*) to detect pair-wise synergic genes. *MIC*(*X*~1~; *X*~2~; *Y*) ranks the top 117, 117 and 110 pair-wise genes for Prostate, DLBCL and Lung1, respectively. After removing repeated genes, we obtain three Top200s (Top200s are shown in the [Supplementary Material Table S1--S3](#S1){ref-type="supplementary-material"}). We compare our *MIC*(*X*~1~; *X*~2~; *Y*) results with the results from four above mentioned reference selection methods. Clearly, the Top200s selected by *MIC*(*X*~1~; *X*~2~; *Y*) has little overlap with the Top200s selected by the others ([Figs 9](#f9){ref-type="fig"}, [10](#f10){ref-type="fig"} and [11](#f11){ref-type="fig"}). We, therefore, deduce that *MIC*(*X*~1~; *X*~2~; *Y*) can discover new synergic genes and that the other four reference feature selection methods can only discover genes that are individually discriminant.

Synergic gene justification
---------------------------

We initially validate these synergic genes according to their prediction performance with a supported vector classifier (SVC). SVC is available at <http://prtools.org/> software/. [Fig. 12](#f12){ref-type="fig"}, illustrates the 10-fold cross-validation prediction accuracies using genes from Top1 to the Top200 selected by *MIC*(*X*~1~; *X*~2~; *Y*), as well as by *MIC*(*X*; *Y*), MRMR, SVM-RFE and TSG. *MIC*(*X*~1~; *X*~2~; *Y*) receives comparable accuracies. This indicates that these synergic genes have sufficient ability to distinguish tissue and cancer types, from the perspective of machine learning.

Do the synergic genes selected by *MIC*(*X*~1~; *X*~2~; *Y*) have any biological relevance to tissue or cancer type? This is particularly relevant considering that even a random set of genes may be a good predictor of cancer sample definition[@b37]. Therefore, we further validated these synergic genes, using the Prostate dataset as an example, according to GO annotation and OUgene database.

We used the GATHER system[@b38] (<http://gather.genome.duke.edu/>) to query GO annotations associated with the Top200s selected by the five methods, as shown in [Fig. 13](#f13){ref-type="fig"}. Although there is little overlap between the genes selected by *MIC*(*X*~1~; *X*~2~; *Y*) and the genes selected by the four reference methods ([Figs 9](#f9){ref-type="fig"}, [10](#f10){ref-type="fig"} and [11](#f11){ref-type="fig"}), synergic genes share the same four heavily marked terms with genes that are individually discriminant ([Fig. 13](#f13){ref-type="fig"}). These four heavily marked GO terms are "cellular macromolecule metabolism," "nucleobase, nucleoside, nucleotide and nucleic acid metabolism," "protein metabolism," and "regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism".

The current version of OUgene, a disease associated, over-expressed and under-expressed gene database, includes 7,238 gene entries, 1,480 diseases entries, and 56,442 PubMed links. We ranked the Top200 synergic genes out of the 12,600 genes in the Prostate dataset using *MIC*(*X*~1~; *X*~2~; *Y*). Of these Top200, 67 tumorigenesis genes were queried against OUgene, and 18 of them have been reported related to prostate cancer[@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56] ([Table 4](#t4){ref-type="table"}).

Combined synergic and individual effect genes to improve the prediction performance
-----------------------------------------------------------------------------------

The MicroArray Quality Control (MAQC)-II project provided benchmark datasets for the development and validation of microarray-based predictive models[@b57]. We use the Breast Cancer dataset from MAQC-II to further evaluate the reliability of *MIC*(*X*~1~; *X*~2~; *Y*). This dataset is used to predict the pre-operative treatment response (pCR) and estrogen receptor status (erpos). It was originally grouped into two groups: a training set containing 130 samples (33 positivesand 97 negatives for pCR, 80 positives and 50 negatives for erpos), and a validation set containing 100 samples (15 positives and 85 negatives for pCR, 61 positives and 39 negatives for erps). Raw probe data (CEL files) for a set of Affymetrix Human Genome U133A Array microarray assays were obtained from GEO (GSE20194). The microarray chip had probe sets for 22283 features, which were normalized and summarized using the Robust Multi-array Average (RMA) method[@b58] on perfect match probes only. Sequential forward selection (SFS) is used to select individually discriminant genes and synergic genes with MIC(*X*; *Y*) and MIC(*X*~1~; *X*~2~; *Y*), respectively: (i) Rank the genes separately by *MIC*(*X*; *Y*) or *MIC*(*X*~1~; *X*~2~; *Y*); (ii) select the Top200 genes (Listed in [supplemental material Table S4--S7](#S1){ref-type="supplementary-material"}), and conduct 10-fold cross-validation (CV10) for the training sets based on SVC. Accuracy was denoted as CV10~*w*~ (*w* = 1, .... 200); (iii) the genes with the highest CV10 accuracy were selected as informative genes for validation. We use the accuracy and Matthew correlation coefficient (*MCC*) to evaluate the predictive power of the analysis.

Here *TP*, *TN*, *FP*, *FN* denote true positives, true negatives, false positives and false negatives respectively. Greater accuracy and *MCC* represent better prediction ability of a model.

As shown in [Table 5](#t5){ref-type="table"}, for Breast erops, the accuracies of individual model and synergic model are 89% and 90%, the *MCC*s are 0.77 and 0.79, respectively. If we integrate the two models, the accuracy and *MCC* of combined model are improved into 92% and 0.83, respectively (Better results may be achieved while the redundancies among genes are removed). Similar improved effects are observed in the "Breast pCR" dataset analysis. These results demonstrate that synergic genes selected by *MIC*(*X*~1~; *X*~2~; *Y*) enhance the individually discriminant model for improving prediction performance.

Discussion
==========

We scanned the Top200s genes selected by *MIC*(*X*~1~; *X*~2~; *Y*) on Prostate and Breast cancer datasets, and summarized three representative patterns of pair-wise synergy and their corresponding theoretic distribution ([Fig. 14](#f14){ref-type="fig"}). Pattern I ([Fig. 14A,B,F](#f14){ref-type="fig"}) results from the typical synergy of [Fig. 4](#f4){ref-type="fig"}, Pattern II ([Fig. 14C,D,G](#f14){ref-type="fig"}) results from the function *y* = *x*~1~--*x*~2~ ([Fig. 5B](#f5){ref-type="fig"}), and Pattern III ([Fig. 14E,H](#f14){ref-type="fig"}) results from the function *y* = \|*x*~1~ *--* *x*~2~\| ([Fig. 5C](#f5){ref-type="fig"}). These patterns offer an efficient tool to infer pathogenic mechanism, even to provide a quantitative model, of pair-wise synergy genes. For Pattern I, *Gene A* and *Gene B* both could be on-off oncogenes ([Fig. 14A](#f14){ref-type="fig"}) or tumor suppressor genes ([Fig. 14B](#f14){ref-type="fig"}) which inhibit each other. For Pattern II, one could be an oncogene, and the other could be a tumor suppressor gene. Pattern III is similar to Pattern I, but *Gene A* and *Gene B* both could be non on-off oncogenes. The results indicate that although the synergy pattern is diversified in real-world datasets, the *MIC*(*X*~1~; *X*~2~; *Y*) method can explore them well. For the pair-wise synergy *ERBB2*-*PAPSS1*, they have been widely reported to correlate with breast cancer[@b59][@b60][@b61][@b62], as well as the *ENO1- PTP4A2* pair[@b63][@b64][@b65][@b66]. For the *BRF2*-*LIPIN1* pair, *BRF2* is related to tumor angiogenesis[@b67]. *LIPIN1* has been reported to correlate with non-tumorous diseases such as rhabdomyolysis[@b68], Type 2 diabetes[@b69], metabolic syndrome[@b70] and acute myoglobinuria[@b71]. Recently, *LIPIN1* was reported to regulate breast adenocarcinoma cell proliferation rate[@b72]. For the *SDC4-LINC01278* pair, *SDC4* has been reported to correlate with tumors[@b73], but *LINC01278* has not. For the *RGS9*-*DIAPH2* pair, neither of them has been reported to correlate with cancer. However, *MIC*(*X*~1~; *X*~2~; *Y*) suggests that *LINC01278*, *RGS9* and *DIAPH2* are important informative genes for prostate tumors, and should be given proper attention.

"MIC is a great step forward, but there are many more steps to take"[@b32]. In this article we took such a step---the extension of two variables to three variables which consider pair-wise interaction. Based on "exploring various binning strategies with different number of bins", Reshef *et al*.[@b30] employed a clump (points in the same clump to be a unit) partition technique to reduce computing time and improve estimation accuracy of MI in a two-dimensional space. This technique does not work in a three-dimensional space, because the definition of clump/superclump has changed. We re-defined superclumps as "points in the same superclump to be a unit in the same *class*, with the rank of x~2~-axis" for considering three variables as a whole, and designed a novel algorithm illustrated in [Fig. 3](#f3){ref-type="fig"} to overcome this barrier. However, complicated diseases such as cancer are often related to collaborative effects involving interactions of multiple genes. Multivariate analysis, just as Anastassiou group[@b11][@b15][@b16][@b17], Park *et al*.[@b19] and Shiraishi *et al*.[@b20] did, is going to be the trend. An extension from *MIC*(*X*~1~; *X*~2~; *Y*) to MIC-based multivariate association networks is therefore still desire.
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![Synergic pairs conducted by function.\
*Y* = \|*X*1 -- *X*2\|(*n* = 200). *Y* is binarized with a median. Red point: positive sample. Green point: negative sample.](srep30672-f1){#f1}

![Examples of scatter plots of discretization for gene expression.\
(**A,B**) are real-word gene expression values for prostate dataset[@b74] and yeast dataset[@b75]; the values of *HTB1* gene are binarized with 0. C and D are simulation datasets from *Y* = 4·*X*^2^ and *Y* = sin (4·π·*X*), *Y* is binarized with 0.5 and 0, respectively. Red point: positive sample. Green point: negative sample.](srep30672-f2){#f2}

![Schematic of getting superclumps partition for three variables.\
The points with the same color belong to the same superclump.](srep30672-f3){#f3}

![*Y* completely determined by the *synergy* between *X*~1~ and *X*~2~.\
*X*~1~ and *X*~2~∈\[10, 30\], and result from binarization vector of *X*~1~ and *X*~2~, respectively. *Y* = (*n* = 1000). Green and red dots represent *Y* = 1 and *Y* = 0, respectively.](srep30672-f4){#f4}

![Ten noiseless functions with *Y* = *f* (*X*~1~, *X*~2~).\
*Y* is binarized with median, green and red dots represent *Y*=1 and *Y*=0, respectively.](srep30672-f5){#f5}

![Overlaps among the Top200s selected by *MIC*(*X*; *Y*), MRMR, SVM-RFE and TSG in the Prostate dataset.](srep30672-f6){#f6}

![Overlaps among the Top200s selected by *MIC*(*X*; *Y*), MRMR, SVM-RFE and TSG in the DLBCL dataset.](srep30672-f7){#f7}

![Overlaps among the Top200s selected by *MIC*(*X*; *Y*), MRMR, SVM-RFE and TSG in the Lung dataset.](srep30672-f8){#f8}

![Overlaps between the Top200 selected by *MIC*(*X*~1~; *X*~2~; *Y*) and the Top200s selected by *MIC*(*X*; *Y*), MRMR, SVM-RFE and TSG in the Prostate dataset.](srep30672-f9){#f9}

![Overlaps between the Top200 selected by *MIC*(*X*~1~; *X*~2~; *Y*) and the Top200s selected by *MIC*(*X*; *Y*), MRMR, SVM-RFE and TSG in the DLBCL dataset.](srep30672-f10){#f10}

![Overlaps between the Top200 selected by *MIC*(*X*~1~; *X*~2~; *Y*) and the Top200s selected by *MIC*(*X*; *Y*), MRMR, SVM-RFE and TSG in the Lung dataset.](srep30672-f11){#f11}

![Prediction accuracy of five feature selection methods combined with SVC Classifier over three datasets.](srep30672-f12){#f12}

![GO annotations for the Top200s selected by different methods in the Prostate dataset.\
Deeper colors of one point in the figure means the terms covered with more genes. We have removed the terms in which the sum of genes number is less than 25 across all methods.](srep30672-f13){#f13}

![Three representative patterns of pair-wise synergy identified by *MIC*(*X*~1~, *X*~2~: *Y*) method.\
(**A--E)** are from real-world datasets, (**F--H**) are the corresponding hypothetical extreme examples.](srep30672-f14){#f14}

###### A typical pair-wise synergy between *X*~1~ and *X*~2~.

  *Y*    *X*~1~   *X*~2~   *X*~1~ ⊕ *X*~2~
  ----- -------- -------- -----------------
  −        1        1             0
  −        0        0             0
  \+       1        0             1
  \+       0        1             1

⊕ is an exclusive-or operation.

###### Mean scores of the three components and the joint effect for 10 noiseless functions (*n* = 1000, 1000 replicates).

  Function    Domain of *X*~1~   Domain of *X*~2~      *Y* = *f*(*X*~1~, *X*~2~)       *MIC*(*X*~1~; *X*~2~; *Y*)   *MIC*(*X*~1~; *Y*)   *MIC*(*X*~2~; *Y*)   Joint effect
  ---------- ------------------ ------------------ ---------------------------------- ---------------------------- -------------------- -------------------- --------------
  A               \[0, 1\]           \[0, 1\]                  x~1~+x~2~                         0.3667                   0.3817               0.3798            1.1283
  B               \[0, 1\]           \[0, 1\]                 x~1~*−*x~2~                        0.3793                   0.3824               0.3663            1.1280
  C               \[0, 1\]           \[0, 1\]                ABS(x~1~−x~2~)                      0.8222                   0.1287               0.1281            1.0790
  D               \[0, 1\]           \[0, 1\]                  x~1~×x~2~                         0.3215                   0.4134               0.4144            1.1493
  E               \[0, 1\]           \[0, 1\]                  x~1~/x~2~                         0.3835                   0.3804               0.3653            1.1292
  F             \[5, 23.3\]        \[5, 23.3\]             10^x^~1~+10^x^~2~                     0.2390                   0.4657               0.4628            1.1675
  G               \[0, 1\]           \[0, 1\]          ABS(1000^x^~1~−1000^x^~2~)                0.4555                   0.3386               0.3381            1.1322
  H               \[0, 1\]           \[0, 1\]       ABS(ABS(x~1~−0.5)−ABS(x~2~−0.5))             0.7080                   0.1295               0.1298            0.9672
  I             \[0, 3.13\]       \[1.5, 4.75\]     LOG~2~(ABS(SIN(x~1~)−COS(x~2~)))             0.2853                   0.3824               0.4274            1.0950
  J               \[0, 3\]           \[0, 3\]             SIN(x~1~)−SIN(x~2~)                    0.3044                   0.3848               0.3832            1.0723

###### Three binary-class gene expression datasets.

  Dataset     No. of Genes   No. of samples   No. of samples in class I   No. of samples in class II   Reference
  ---------- -------------- ---------------- --------------------------- ---------------------------- -----------
  Prostate       12600            102                    52                           50                [@b74]
  Lung           12533            181                    150                          31                [@b76]
  DLBCL           7129             77                    58                           19                [@b77]

###### The 67 cancer related genes out of the Top200 selected by *MIC*(*X*~1~; *X*~2~; *Y*) in the Prostate dataset.

  Genes                                                                                                                 Related tumors
  --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ABCB1, AMACR, CAV1, CCND1, CSF2, DPT, E2F3, ETV4, GOT2, GREB1, HBP1, HCLS1, HMGA1, PAX2, SFRP1, SOX9, TRAF4, ZNF143   Prostate
  ABCA4, CASC3, CD81, COMP, MAP1LC3B, PPP3CA, SLN, TFAP2C, TRO                                                          Breast cancer
  DSC2, EDG4, FBLN1, GALNT3, KRT10, NDN                                                                                 Ovarian carcinomas
  CTSE, DNAJA1, LY6E                                                                                                    Pancreatic cancer
  NR2F6, TERF2, TPP1                                                                                                    Colorectal cancer
  PCBP2, RAF1                                                                                                           Glioma
  COL6A1, CYP2A13                                                                                                       Lung cancer
  PPP2R5C                                                                                                               leukemia
  PPP6C                                                                                                                 Hepatocellular carcinoma
  AGXT                                                                                                                  Lymphomas
  DIO2                                                                                                                  Thyroid carcinomas
  DYRK2                                                                                                                 Lung adenocarcinomas
  FGFBP1                                                                                                                Gallbladder cancer
  PROP1                                                                                                                 Pituitary adenoma
  PITX3                                                                                                                 Liposarcoma
  RFP                                                                                                                   Oligodendroglioma
  CDKN1C                                                                                                                Adrenal adenoma
  VAV1                                                                                                                  Ovarian carcinomas, Leukemia
  JAG1                                                                                                                  Breast cancer, Cervical cancer
  PHGDH                                                                                                                 Breast cancer, Cervical cancer
  HYAL1                                                                                                                 Breast cancer, Laryngeal carcinoma, Pancreatic cancer
  NCAM1                                                                                                                 Sarcoidosis, Leukemia, Lymphomas
  PPP2R2A                                                                                                               Squamous cell carcinoma, Leukemia, Esophageal cancer, Lung cancer
  GATA2                                                                                                                 Breast cancer, Leukemia, Neuroblastoma, Choriocarcinoma
  THBS2                                                                                                                 Breast cancer, Adenocarcinoma, Colorectal cancer, Ovarian carcinomas
  WNT5A                                                                                                                 Breast cancer, Leukemia, Pancreatic cancer, Ovarian carcinomas, Melanoma
  TGM2                                                                                                                  Adenocarcinoma, Neuroblastoma, Pancreatic cancer, Ovarian carcinomas, Lung cancer, Hepatocellular carcinoma, Melanoma
  GSTP1                                                                                                                 Squamous cell carcinoma, Leukemia, Lymphomas, Ovarian carcinomas, Lung cancer, Hepatocellular carcinoma, Melanoma, Colon cancer, Glioblastoma multiforme, Astrocytoma, Osteosarcoma
  BAI1                                                                                                                  Carcinoma
  PTP4A3                                                                                                                Carcinoma
  TGFBR3                                                                                                                Carcinoma

###### Results of independent test for erpos and pCR of Breast cancer.

  Dataset                                                                            Model                                                  Number of genes   Validation accuracy   Validation *MCC*
  ---------------------------------------------------------------------------------- ----------------------------------------------------- ----------------- --------------------- ------------------
  Breast                                                                                                                                                                           
  erpos                                                                              Individual model, genes selected by *MIC*(*X*; *Y*)           8                  89%                 0.77
  Synergic model, genes selected by *MIC*(*X*~1~; *X*~2~; *Y*)                       34                                                           90%                0.79          
  Combined model, genes selected by *MIC*(*X*; *Y*) and *MIC*(*X*~1~; *X*~2~; *Y*)   42                                                           92%                0.83          
  Candidate model in reference [@b51]                                                6                                                            87%                0.73          
  Best model in reference [@b51]                                                     316                                                          90%                0.79          
  Breast                                                                                                                                                                           
  pCR                                                                                Individual model, genes selected by *MIC*(*X*; *Y*)          59                  82%                 0.36
  Synergic model, genes selected by *MIC*(*X*~1~; *X*~2~; *Y*)                       32                                                           81%                0.35          
  Combined model, genes selected by *MIC*(*X*; *Y*) and *MIC*(*X*~1~; *X*~2~; *Y*)   91                                                           84%                0.37          
  Candidate model in reference [@b51]                                                206                                                          72%                0.30          
  Best model in reference [@b51]                                                     40                                                           73%                0.38          

[^1]: These authors contributed equally to this work.
